Home | Welcome to Contract Pharma   
Last Updated Monday, November 24 2014
Print RSS Feed

FDA Fast Tracks Synta's NSCLC Treatment



By Gil Roth



Published September 12, 2013
Related Searches: Phase III contractpharma Development Manufacturing
The FDA has granted Fast Track designation to the investigation of ganetespib, Synta Pharmaceuticals' lead Hsp90 inhibitor drug candidate, to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen. FDA’s Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs that are intended to treat serious medical conditions and that demonstrate the potential to fill unmet medical needs.

“We are very pleased that FDA has granted this important designation to the ganetespib development program,” said Safi Bahcall, President and CEO of Synta. “We look forward to continued progress and bringing ganetespib to cancer patients as quickly as possible.”

Ganetespib is currently being evaluated as a treatment of non-small cell lung adenocarcinoma in the GALAXY program, consisting of the GALAXY-1 Phase IIb/III all-comer trial and the GALAXY-2 Phase III trial enriched for patients most likely to benefit from ganetespib treatment.

Tom Wilson, Synta Pharmaceuticals' vice president of Quality, will give the presentation, "Managing Virtual Manufacturing: The Perspective from a Small Company," at Contracting & Outsourcing 2013 (Sept. 19-20). For more information, visit the conference site!



blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On